Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 351

2.

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.

Davidson JR, DuPont RL, Hedges D, Haskins JT.

J Clin Psychiatry. 1999 Aug;60(8):528-35.

PMID:
10485635
3.
4.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
5.

Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder.

Kroenke K, Messina N 3rd, Benattia I, Graepel J, Musgnung J.

J Clin Psychiatry. 2006 Jan;67(1):72-80.

PMID:
16426091
6.

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E.

JAMA. 2000 Jun 21;283(23):3082-8.

PMID:
10865302
8.
9.

Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study.

Nimatoudis I, Zissis NP, Kogeorgos J, Theodoropoulou S, Vidalis A, Kaprinis G.

Int Clin Psychopharmacol. 2004 Nov;19(6):331-6.

PMID:
15486518
10.
12.

The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia.

Ballús C, Quiros G, De Flores T, de la Torre J, Palao D, Rojo L, Gutiérrez M, Casais L, Riesgo Y.

Int Clin Psychopharmacol. 2000 Jan;15(1):43-8.

PMID:
10836286
14.
15.

Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.

Sonawalla SB, Spillmann MK, Kolsky AR, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M.

J Clin Psychiatry. 1999 Sep;60(9):580-3.

PMID:
10520975
16.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
17.
18.

A large open-label study of venlafaxine in depressed outpatients by community-based physicians.

Joffe RT, Marshall AM, Lee DK.

J Clin Psychiatry. 1998 Oct;59(10):515-20.

PMID:
9818632
19.

Nefazodone in the treatment of elderly patients with depressive disorders: a prospective, observational study.

Saiz-Ruiz J, Ibañez A, Díaz-Marsá M, Arias F, Carrasco JL, Huertas D, Martín-Carrasco M, Moreno I, Rico-Villademoros F.

CNS Drugs. 2002;16(9):635-43.

PMID:
12153334
20.

Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.

Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D.

Depress Anxiety. 2002;16(1):4-13.

PMID:
12203668

Supplemental Content

Support Center